Related Experiment Video
Updated: Aug 12, 2026

Assessing the Innate Sensing of HIV-1 Infected CD4+ T Cells by Plasmacytoid Dendritic Cells Using an Ex vivo Co-culture System.
Published on: September 1, 2015
Interleukin-16 inhibits human immunodeficiency virus type 1 entry and replication in macrophages and in dendritic
M J Truong1, E C Darcissac, E Hermann
1Institut Pasteur de Lille, INSERM U167, 59019 Lille Cedex, France.
Insights
Recombinant interleukin-16 (rIL-16) effectively suppresses human immunodeficiency virus type 1 (HIV-1) replication in antigen-presenting cells (APCs). This cytokine blocks viral entry and reduces proviral DNA, showing potential for HIV treatment.
Area of Science:
- Immunology
- Virology
- Cell Biology
Background:
- Recombinant interleukin-16 (rIL-16) inhibits HIV-1 replication in CD4(+) T cells.
- The impact of rIL-16 on HIV-1 replication in antigen-presenting cells (APCs) remains uncharacterized.
Purpose of the Study:
- To investigate the effect of rIL-16 on HIV-1 replication in APCs.
- To determine the mechanism of rIL-16's anti-HIV activity in macrophages and dendritic cells.
Main Methods:
- Assessed HIV-1 replication in monocyte-derived macrophages and dendritic cells treated with rIL-16.
- Measured viral RNA transcripts and reverse transcriptase levels.
- Evaluated the effect of rIL-16 timing and its impact on viral entry and proviral DNA.
Main Results:
- rIL-16 demonstrated potent HIV-1 suppression in acutely infected APCs.
- The suppressive effect required early rIL-16 exposure post-infection.
- rIL-16 blocked HIV-1 entry and reduced proviral DNA in APCs without affecting beta-chemokines or enhancing cytokines.
Conclusions:
- rIL-16 plays a critical role in protecting APCs from HIV-1 infection.
- These findings support the potential therapeutic application of rIL-16 for HIV disease treatment.
Abstract:
Recombinant interleukin-16 (rIL-16) has been found to inhibit human immunodeficiency virus type 1 (HIV-1) replication in acutely or endogenously infected CD4(+) T cells. However, the effect of rIL-16 on HIV-1 replication in antigen-presenting cells (APCs) is still unknown. We show here a potent HIV-suppressive activity of rIL-16 in acutely infected monocyte-derived macrophages and dendritic cells determined by the levels of viral RNA transcripts or of viral reverse transcriptase in culture supernatants. The observed effect was dependent on the presence of rIL-16 early after infection and could not be induced by a 24-h treatment of cells with the cytokine prior to infection. Using macrophage-tropic and dually tropic primary isolates, we also showed that the addition of rIL-16 to cell cultures only during the infection period was effective in blocking virus entry and reducing proviral DNA levels in APCs. However, the anti-HIV activity of rIL-16 could not be linked to the induction of virus-suppressive concentrations of beta-chemokines or to the inhibition of HIV-enhancing cytokines. These findings establish a critical role for rIL-16 in protecting APCs against HIV-1 infection and lend further support to its potential use in the treatment of HIV disease.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Inhibitors of Viral Protein Synthesis
Inhibitors of Virion Maturation and Assembly

